MedTrace Logo

Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma

NCT01572688 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-08-02

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and effectiveness of melphalan for injection for autologous stem cell transplant in multiple myeloma

Conditions

Interventions

DRUG

Melphalan

powder for injection, 200mg/m2, uses after reconstituted within 24 hours

Sponsors & Collaborators

  • Shandong Lanjin Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Lugui Qiu, master · Chinese Academy of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01572688 on ClinicalTrials.gov